顺铂联合放疗治疗中晚期食管癌预后分析

目的：重点研究和探讨顺铂联合放疗治疗中晚期食管癌患者的临床疗效及安全性。方法回顾性分析我院2010年1月1日~2012年12月31日期间收治的60例中晚期食管癌患者的临床资料。将患者随机分为两组，对照组总计30例应用放疗进行治疗；观察组总计30例在对照组的治疗基础上加用顺铂联合治疗。然后将两组数据结果进行分析，分析探讨两组患者疗效、患者满意率以及不良反应的结果。结果通过对我院收治的60例中晚期食管癌患者的临床资料进行分析，观察组患者的治疗效果、患者满意率、不良反应均显著好于对照组（P＜0.05）。结论顺铂联合放疗治疗中晚期食管癌患者具有很好的临床疗效，并且具有良好的安全性，目前已经成为治疗中晚期食管癌患者的主要方法，对我国治疗中晚期食管癌的发展具有重要价值。

Analysis on prognosis of moderate and advanced esophageal carcinoma by cisplatin combined with radiotherapy

Objective To focus on and explore the clinical efficacy and safety of cisplatin combined with radiotherapy in the treatment of patients with moderate and advanced esophageal carcinoma. Methods The clinical data of 60 patients with moderate and advanced esophageal carcinoma who were treated in our hospital from January 1, 2010 to December 31, 2012 were studied and compared by using the retrospective analysis method. All patients were randomly divided into the two groups, 30 cases of the control group were given radiotherapy, while 30 cases of the observation group were treated with cisplatin based on the use of radiotherapy. Then the efficacy, patient＇s satisfaction rate and adverse reactions of patients in the two groups were analyzed and explored. Results The analysis of clinical data of 60 patients with moderate and advanced esophageal carcinoma treated in our hospital showed that the efficacy, patient＇s satisfaction rate and adverse reactions of patients in the observation group were significantly better than those in the control group（P〈0.05）. Conclusion Cisplatin combined with radiotherapy in the treatment of patients with moderate and advanced esophageal carcinoma has good clinical efficacy, good security, and has become the main treatment method for patients with moderate and advanced esophageal carcinoma now, has important value for the development of moderate and advanced esophageal carcinoma treatment in our country.